The core competencies of IASON include concepts for the distribution of pharmaceuticals with a very short shelf-life and for the increase in efficiency of the process sequences. Furthermore, we implement safety tools in the case of radioactivity and to guarantee modern hygienic standards for the handling of pharmaceuticals.
Further areas of competence of IASON include the oncology (early detection and treatment of cancer etc.), the neurology (diagnosis and surgical planning) and the cardiology (detection and treatment of heart diseases). Each area has an investment volume of 4 to 10 billion USD.
In addition, IASON supplies highly sensitive immunoassays to medical institutions, which are used in the diagnosis and treatment of many diseases.
Areas
Permanent further Development
Mag. Christoph Artner founded the company IASON GmbH, which has its headquarters in Graz, in 1994. From the beginning, nuclear medicine was the target group. The company’s purpose was the trade in medical devices. By specialising in the areas of thyroid gland and bone metabolism, the company gradually built up a large product range. Immunoassays which measure all hormones, tumour markers, infection serology and autoimmunology were added to the product range.
Today, IASON develops and manufactures lab kits and specialised products for the target groups nuclear medicine and laboratory medicine and supplies them to customers worldwide, thus making this area an important core competency of the company.
Competences
Leading products for Europe
With the full market approval of Efdege® ([18F] Fluorodeoxyglucose) in 15 EU countries in 2004, IASON achieved its first and biggest milestone as a pharmaceutical company.
Based on strong research focus, two further pharmaceuticals could be approved (IASOdopa® 2006 in four countries, IASOflu® 2009 in France, 2010 in 12 further countries) by 2009. With full market approval of IASOcholine® ([18F] Fluorocholine) in France in 2010, IASON succeeded in completing the next step. IASOcholine® is the first PET pharmaceutical worldwide, which obtained full market approval on the basis of an internal clinical study. IASOcholine® will initially be approved in four other EU countries and IASON will also aim at an approval procedure with the FDA (American Food and Drug Administration). Thus, IASON has taken the leading role worldwide as opinion leader with regard to the new approval of radiopharmaceuticals both on the market and towards the approval authorities.
With IASOdopa® ([18F] Fluordopa, in France, Germany, Austria and Italy) and IASOflu® (sodium [18F] fluoride), IASON is the first pharmaceutical company worldwide which has more than one approved product for PET. With these full market approvals, IASON has build up a leading competence in the area of regulatory affairs and is now considered to lead the way.
IASON, with its head office in Graz, was founded in 1994 and has its origins in the trade of innovative medical technology products. As a specialist for the production of radioactive pharmaceuticals, IASON helped to bring the method of positron-emission-tomography (PET) to Austria in the late 1990ies.
Turnkey projects (Build-Operate-Transfer)
Running Cyclotron-based Pharmaceutical Production Centers Worldwide
Within our consultancy program, our international expert team of engineers and pharmacists is offering professional guidance for the all complex aspects of the operation of such production centres, such as
Clinical Research Programs
Within our consultancy program, our international expert team is offering the following expertise:
For inquiries please contact us, we will be happy to assist you!
Curium acquired IASON in June of 2021, further expanding its footprint in Europe for its broad portfolio of life saving diagnostic solutions. Learn more on Curium’s website
